Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03479125 · ClinicalTrials.gov registry record
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
A clinical trial, sponsored by Conatus Pharmaceuticals.
- Terminated
- Registry status
- 40
- Enrollment target
NCT03479125 is a clinical trial that was terminated before completion, run by Conatus Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT03479125 was terminated before completion, sponsored by Conatus Pharmaceuticals.
- TERMINATED
- Registry status
- 40 participants
- Enrollment target
Study Summary
A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo. Subjects must have been enrolled in a prior IDN-6556 study to be eligible.
Interventions
- DIAGNOSTIC_TEST Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2019-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03479125
The ClinicalTrials.gov registry entry for NCT03479125 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ultrasound is the first listed.
NCT03479125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03479125 about?
NCT03479125 is a clinical study titled "Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo". A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo. Subjects must have been enrolled in a prior IDN-6556 study to be eligible.
What is the current status of trial NCT03479125?
This trial is currently terminated. The enrollment target is 40 participants. The study started on 2018-02-27. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03479125?
The interventions under investigation include: Ultrasound (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03479125?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.